Ischemia and reperfusion in pancreas

Area of Science:

• Biomedical Science
• Pathophysiology
• Gastroenterology

Background:

• Ischemic diseases, particularly affecting the heart and brain, are leading causes of mortality globally.
• Ischemia/reperfusion injury disrupts microcirculation, leading to tissue damage and organ dysfunction.
• Oxygen-derived free radicals and polymorphonuclear leukocytes play key roles in ischemic cell injury.

Purpose of the Study:

• To investigate the role of ischemia/reperfusion injury in pancreatic pathogenesis.
• To explore the involvement of the kallikrein-kinin system in acute pancreatitis.
• To evaluate the therapeutic potential of bradykinin antagonists in mitigating pancreatic ischemia/reperfusion injury.

Main Methods:

• Description of the pathophysiology of ischemia/reperfusion injury in the pancreas.
• Examination of pancreatic microcirculation and morphological changes in a reversible ischemia model.
• Assessment of the effects of bradykinin antagonists (HOE 140 and CP-0597) on pancreatic function post-ischemia/reperfusion.

Main Results:

• Ischemia/reperfusion is implicated in acute pancreatitis pathogenesis.
• The kallikrein-kinin system contributes to inflammation and microcirculatory disturbances in ischemia/reperfusion injury.
• Bradykinin antagonists demonstrated potential in preserving pancreatic functional integrity after ischemia/reperfusion.

Conclusions:

• Bradykinin antagonists represent a promising therapeutic strategy for pancreatic ischemia/reperfusion injury.
• Targeting the kallikrein-kinin system may offer a novel approach to managing acute pancreatitis.
• Further research into bradykinin antagonism could lead to improved treatments for pancreatic dysfunction following ischemic events.